Investigating the prognostic value of digital mobility outcomes in patients with chronic obstructive pulmonary disease: a systematic literature review and meta-analysis

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Buttery, Sara C.
  • dc.contributor.author Buekers, Joren
  • dc.contributor.author Delgado Ortiz, Laura
  • dc.contributor.author García Aymerich, Judith
  • dc.contributor.author Gimeno Santos, Elena, 1980-
  • dc.contributor.author Koch, Sarah
  • dc.contributor.author Hopkinson, Nicholas S.
  • dc.date.accessioned 2024-03-18T07:43:27Z
  • dc.date.available 2024-03-18T07:43:27Z
  • dc.date.issued 2023
  • dc.description.abstract Background: Reduced mobility is a central feature of COPD. Assessment of mobility outcomes that can be measured digitally (digital mobility outcomes (DMOs)) in daily life such as gait speed and steps per day is increasingly possible using devices such as pedometers and accelerometers, but the predictive value of these measures remains unclear in relation to key outcomes such as hospital admission and survival. Methods: We conducted a systematic review, nested within a larger scoping review by the MOBILISE-D consortium, addressing DMOs in a range of chronic conditions. Qualitative and quantitative analysis considering steps per day and gait speed and their association with clinical outcomes in COPD patients was performed. Results: 21 studies (6076 participants) were included. Nine studies evaluated steps per day and 11 evaluated a measure reflecting gait speed in daily life. Negative associations were demonstrated between mortality risk and steps per day (per 1000 steps) (hazard ratio (HR) 0.81, 95% CI 0.75-0.88, p<0.001), gait speed (<0.80 m·s-1) (HR 3.55, 95% CI 1.72-7.36, p<0.001) and gait speed (per 1.0 m·s-1) (HR 7.55, 95% CI 1.11-51.3, p=0.04). Fewer steps per day (per 1000) and slow gait speed (<0.80 m·s-1) were also associated with increased healthcare utilisation (HR 0.80, 95% CI 0.72-0.88, p<0.001; OR 3.36, 95% CI 1.42-7.94, p=0.01, respectively). Available evidence was of low-moderate quality with few studies eligible for meta-analysis. Conclusion: Daily step count and gait speed are negatively associated with mortality risk and other important outcomes in people with COPD and therefore may have value as prognostic indicators in clinical trials, but the quantity and quality of evidence is limited. Larger studies with consistent methodologies are called for.
  • dc.description.sponsorship This work was supported by the Mobilise-D project; the Mobilise-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This publication reflects the authors’ views and neither IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein. H. Demeyer is a postdoctoral research fellow of the FWO-Flanders. ISGlobal acknowledges support from the grant CEX2018–000806-S funded by MCIN/AEI/ 10.13039/501100011033, and the Generalitat de Catalunya through the CERCA Program and L. Delgado-Ortiz is funded by the following grant: Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113 from ISCIII, and the European Social Fund Plus (ESF+). This research was supported by the NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, the IMI, the European Union, the EFPIA or any Associated Partners. Funding information for this article has been deposited with the Crossref Funder Registry.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Buttery SC, Williams PJ, Alghamdi SM, Philip KEJ, Perkins A, Kallis C et al. Investigating the prognostic value of digital mobility outcomes in patients with chronic obstructive pulmonary disease: a systematic literature review and meta-analysis. Eur Respir Rev. 2023 Nov 22;32(170):230134. DOI: 10.1183/16000617.0134-2023
  • dc.identifier.doi http://dx.doi.org/10.1183/16000617.0134-2023
  • dc.identifier.issn 0905-9180
  • dc.identifier.uri http://hdl.handle.net/10230/59450
  • dc.language.iso eng
  • dc.publisher European Respiratory Society
  • dc.relation.ispartof Eur Respir Rev. 2023 Nov 22;32(170):230134
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/820820
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/CEX2018–000806-S
  • dc.rights © The authors 2023. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0 (http://creativecommons.org/licenses/by-nc/4.0/). For commercial reproduction rights and permissions contact permissions@ersnet.org
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
  • dc.subject.other Pulmons--Malalties obstructives
  • dc.title Investigating the prognostic value of digital mobility outcomes in patients with chronic obstructive pulmonary disease: a systematic literature review and meta-analysis
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion